Abstract
Background Malaria incidence has plateaued in Sub-Saharan Africa despite Seasonal Malaria chemoprevention’s introduction. Community health workers use a door-to-door delivery strategy to treat children with SMC drugs, but for SMC to be as effective as in clinical trials, coverage must be high over successive seasons.
Methods We used a microplanning model that utilizes raster to estimate population size, generates optimal households visit itinerary, and quantifies SMC coverage based on CHWs’ time investment. CHWs’ performance under current SMC deployment mode was assessed and compared to microplanning.
Results Estimates showed that microplanning significantly reduces CHWs’ walking distance by 25%, increases visited households by 36% (p < 0.001) and increases SMC coverage by 21% (37.3% under current SMC deployment mode up to 58.3% under microplanning, p < 0.001). Optimal visit itinerary alone increased SMC coverage up to 100% in small villages whereas in larger or hard-to-reach villages, filling the gap additionally needed an optimization of the CHW ratio.
Conclusion We estimate that for a pair of CHWs, the daily optimal number of visited children and walking distance should not exceed 45 and 5km respectively. Our work contributes to extend SMC coverage by 21-63% and may have broader applicability for other community health programs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Global Good Fund, Bellevue, WA. JZ was additionally supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1656518
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Statement Data presented here were from publicly available sources and did not require ethical clearance.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon request.